Clinical Trials
UniXell Secures US FDA Clearance for Off-the-Shelf Parkinson’s Cell Therapy, Advancing Dual-China-US Clinical Development
UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA...
June 25, 2026 | News
AnHorn Medicines Secures FDA IND Clearance for First-in-Class CIPN Prevention Candidate
AnHorn Medicines announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuro...
June 24, 2026 | News
China Approves World's First CAR-T Therapy for Solid Tumours
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by...
June 24, 2026 | News
Europe Greenlights BRAFTOVI, Cetuximab and FOLFOX Regimen for Previously Untreated BRAF-Mutant mCRC
uropean approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 de...
June 24, 2026 | News
DoH Abu Dhabi and Sanofi Deepen Partnership to Build Next-Generation Vaccine Innovation Hub
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines...
June 24, 2026 | News
Avance Clinical Expands APAC And China Operations To Accelerate Global Biotech Trials
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pacif...
June 22, 2026 | News
Qihan Biotech’s Universal CAR-T Therapy QT-019B Secures FDA’s ‘Triple Crown’ of Expedited Designations
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...
June 18, 2026 | News
Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat
Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190...
June 18, 2026 | News
Insilico Medicine Achieves First Clinical Milestone for AI-Designed NLRP3 Inhibitor ISM8969
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced it has ach...
June 18, 2026 | News
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast in Lower-Risk Myelodysplastic Syndromes
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 Ha...
June 17, 2026 | News
Dimerix Signs Up to AU$481 Million Licensing Deal with Everest Medicines to Advance Phase 3 Kidney Disease Therapy Across Asia
Dimerix Limited (ASX: DXB), a biopharmaceutical company developing innovative therapies for rare inflammatory diseases, has entered into an exclusive licen...
June 17, 2026 | News
Lilly's Jaypirca Combination Cuts Disease Progression Risk by 45% in Relapsed CLL Phase 3 Trial
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the...
June 16, 2026 | News
QingSong Health and Basel Medical Group Forge Strategic Alliance to Advance AI Healthcare in Southeast Asia
QingSong Health Corp (2661.HK) and Basel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties i...
June 15, 2026 | News
Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data
Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...
June 15, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
